FDA panel thumbs down on Boehringer-Lilly empagliflozin for Type 1 Diabetes

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted 14 – 2 that the benefits of Boehringer Ingelheim and Eli Lilly’s (NYSE:LLY) SGLT2 inhibitor empagliflozin do not outweigh the risks as an adjunct to insulin for adults with type 1 diabetes (T1D).

Empagliflozin, branded as Jardiance, was approved in the U.S. in August 2014 for adults with type 2 diabetes (T2D).

https://seekingalpha.com/news/3519118-fda-ad-com-thumbs-bi-lillys-empagliflozin-t1d